Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CALT NASDAQ:HROW NASDAQ:MNKD NASDAQ:TLMD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCALTCalliditas Therapeutics AB (publ)$40.00$40.00$15.25▼$43.00$1.19B1.7710,339 shsN/AHROWHarrow$33.02-1.3%$32.20$20.85▼$59.23$1.23B0.41470,734 shs249,235 shsMNKDMannKind$3.46-13.3%$3.89$3.45▼$7.63$1.21B1.022.53 million shs9.51 million shsTLMDSOC Telemed$3.00$2.98$0.55▼$8.00$302.52M-1.441.28 million shsN/AThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCALTCalliditas Therapeutics AB (publ)0.00%0.00%0.00%0.00%+2.30%HROWHarrow-1.29%+1.01%+5.29%+39.97%+45.33%MNKDMannKind-13.28%-10.59%-2.26%-25.35%-34.35%TLMDSOC Telemed0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCALTCalliditas Therapeutics AB (publ)N/AN/AN/AN/AN/AN/AN/AN/AHROWHarrow2.4805 of 5 stars3.51.00.00.02.82.50.6MNKDMannKind3.563 of 5 stars3.63.00.00.03.11.71.9TLMDSOC TelemedN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCALTCalliditas Therapeutics AB (publ) 0.00N/AN/AN/AHROWHarrow 3.00Buy$63.8393.32% UpsideMNKDMannKind 3.25Buy$9.86184.89% UpsideTLMDSOC Telemed 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest TLMD, HROW, CALT, and MNKD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/23/2025MNKDMannKindRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$10.00 ➝ $8.007/16/2025MNKDMannKindHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy$9.007/11/2025HROWHarrowCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$76.006/12/2025HROWHarrowBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$62.006/10/2025HROWHarrowWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform5/12/2025HROWHarrowHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$57.00 ➝ $60.00(Data available from 8/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCALTCalliditas Therapeutics AB (publ)$1.60B0.74N/AN/A$1.06 per share37.74HROWHarrow$199.61M6.07$0.13 per share244.62$1.95 per share16.93MNKDMannKind$285.50M3.68$0.12 per share28.75($0.29) per share-11.93TLMDSOC Telemed$94.44M3.20N/AN/A$1.66 per share1.81Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCALTCalliditas Therapeutics AB (publ)-$43.96M-$1.85N/A8.68N/A-30.18%-212.04%-27.96%N/AHROWHarrow-$17.48M-$0.56N/A82.55N/A-10.19%-25.01%-4.27%8/11/2025 (Estimated)MNKDMannKind$27.59M$0.1034.6015.04N/A10.12%-32.41%10.85%N/ATLMDSOC Telemed-$50.54M-$0.57N/A∞N/A-53.52%-34.32%-20.96%N/ALatest TLMD, HROW, CALT, and MNKD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025HROWHarrow$0.01N/AN/AN/A$64.23 millionN/A8/6/2025Q2 2025MNKDMannKind$0.04$0.05+$0.01N/A$77.82 million$76.53 million5/8/2025Q1 2025HROWHarrow$0.02-$0.38-$0.40-$0.50$57.00 million$47.83 million5/8/2025Q1 2025MNKDMannKind$0.03$0.04+$0.01$0.04$75.86 million$78.35 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCALTCalliditas Therapeutics AB (publ)N/AN/AN/AN/AN/AHROWHarrowN/AN/AN/AN/AN/AMNKDMannKindN/AN/AN/AN/AN/ATLMDSOC TelemedN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCALTCalliditas Therapeutics AB (publ)9.442.692.59HROWHarrow2.010.910.85MNKDMannKindN/A2.362.11TLMDSOC Telemed0.523.323.28Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCALTCalliditas Therapeutics AB (publ)2.83%HROWHarrow72.76%MNKDMannKind49.55%TLMDSOC TelemedN/AInsider OwnershipCompanyInsider OwnershipCALTCalliditas Therapeutics AB (publ)2.20%HROWHarrow15.16%MNKDMannKind2.70%TLMDSOC Telemed6.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCALTCalliditas Therapeutics AB (publ)18029.79 million29.14 millionOptionableHROWHarrow18036.69 million31.12 millionOptionableMNKDMannKind400303.93 million295.73 millionOptionableTLMDSOC Telemed226100.84 million93.88 millionOptionableTLMD, HROW, CALT, and MNKD HeadlinesRecent News About These CompaniesThe Woman’s World Expert-Reviewed Glossary of GLP-1, Semaglutide and TelehealthNovember 14, 2024 | yahoo.comTrial reveals success of telemedicine-supported, village doctor–led approach to managing atrial fibrillationSeptember 2, 2024 | msn.comExplore the Innovations of Dr. Todd H. Lanman: An Influence in Spinal NeurosurgeryAugust 27, 2024 | usatoday.comComparative Studies in Society and HistoryAugust 24, 2024 | cambridge.orgCFrom science fiction to telemedicine: the surprising 150-year history of long-range medical treatmentAugust 9, 2024 | theconversation.comTTaipei Medical University Hospital successfully advances telemedicine, leveraging technology to provide comprehensive healthcareAugust 9, 2024 | digitimes.comDNavigating telemedicine and online doctors in Louisiana for more 'consumer-centric' careAugust 4, 2024 | nola.comNTelemedicine usage can have unexpected impact on rural communities' access to local careAugust 2, 2024 | msn.comCalifornia's Telemedicine Restrictions Are Forcing Rare Disease Patients To Travel Out of State for CareMay 23, 2024 | reason.comROne reader’s view | Cowlitz County Humane Society director urges expanding telemedicine for petsMay 10, 2024 | tdn.comTSociety ManMay 2, 2024 | bloodhorse.comBAccess to remote learning, telemedicine during extreme weather events ending for millionsMay 2, 2024 | nypost.comNTelemedicine Reduces Rehospitalization, Revascularization in Post-PCI ACS PatientsApril 7, 2024 | medscape.comMTelehealth Improves Hepatitis C Treatment in Patients With Opioid Use DisorderApril 4, 2024 | medpagetoday.comMUT Southwestern, Dallas telemedicine company partner on study to improve heart health in rural communitiesApril 4, 2024 | bizjournals.comMobile pet telehealth app expands offeringsApril 1, 2024 | dvm360.comDBill allowing telemedicine for pets awaits Gov. DeSantis' signatureMarch 11, 2024 | fox13news.comFDallas Trio To Bring ‘Specialists to Patients’ With Rural Cardiac Telemedicine PilotMarch 7, 2024 | dallasinnovates.comDJournal of the Royal Asiatic SocietyFebruary 29, 2024 | cambridge.orgC(LEAD) Gov't to fully allow telemedicine services in case of doctors' collective actionFebruary 19, 2024 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTLMD, HROW, CALT, and MNKD Company DescriptionsCalliditas Therapeutics AB (publ) NASDAQ:CALT$40.00 0.00 (0.00%) As of 08/5/2025Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden.Harrow NASDAQ:HROW$33.02 -0.43 (-1.29%) Closing price 08/6/2025 04:00 PM EasternExtended Trading$31.48 -1.55 (-4.68%) As of 04:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Harrow, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.MannKind NASDAQ:MNKD$3.46 -0.53 (-13.28%) Closing price 08/6/2025 04:00 PM EasternExtended Trading$3.58 +0.12 (+3.50%) As of 05:31 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.SOC Telemed NASDAQ:TLMDSOC Telemed, Inc. provides acute care telemedicine services and technology to hospitals, health systems, physician groups, and government organizations in the United States. The company's Telemed IQ, a cloud-based software platform provides telemedicine solutions. Its telemedicine solutions include teleNeurology, telePulmonology, telePsychiatry, telecardiology, teleCritical Care (ICU), and other specialties. The company was founded in 2004 and is based in Herndon, Virginia. As of April 6, 2022, SOC Telemed, Inc. was taken private. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Joby Deal Gives Blade New Direction, But Stock Lacks Lift How DigitalOcean's Focus Is Fueling Explosive Growth Disney’s Iger-Led Turnaround Gains Traction Can Celsius Stock Keep Its Momentum Going Any Longer? AMD’s Results Sparked a Sell-Off—But That’s Your Buy Signal Rivian Takes Earnings Hit—R2 Could Be the Stock's 2026 Lifeline Does Broadcom Have a VMware Problem? Goldman Eyes Upside in NTNX RSI Stock Soars 22% On Q2 Blowout—Will PENN Match the Momentum? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
